Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Maged Shenouda Buys 60,000 Shares

Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Maged Shenouda purchased 60,000 shares of Relmada Therapeutics stock in a transaction on Tuesday, May 20th. The stock was bought at an average price of $0.52 per share, for a total transaction of $31,200.00. Following the completion of the acquisition, the chief financial officer now owns 288,335 shares in the company, valued at $149,934.20. The trade was a 26.28% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Maged Shenouda also recently made the following trade(s):

• On Monday, May 19th, Maged Shenouda purchased 90,000 shares of Relmada Therapeutics stock. The stock was bought at an average price of $0.49 per share, for a total transaction of $44,100.00.
• On Friday, May 16th, Maged Shenouda purchased 50,000 shares of Relmada Therapeutics stock. The stock was bought at an average price of $0.44 per share, for a total transaction of $22,000.00.

Relmada Therapeutics Stock Performance

Shares of NASDAQ RLMD opened at $0.60 on Wednesday. Relmada Therapeutics, Inc. has a 52-week low of $0.24 and a 52-week high of $4.47. The company has a market cap of $19.82 million, a P/E ratio of -0.21 and a beta of 0.18. The firm’s fifty day moving average is $0.35 and its two-hundred day moving average is $0.77.

Relmada Therapeutics (NASDAQ:RLMD) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.27). As a group, analysts forecast that Relmada Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Relmada Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. purchased a new position in shares of Relmada Therapeutics in the 1st quarter worth $33,000. Renaissance Technologies LLC grew its stake in shares of Relmada Therapeutics by 535.5% in the 4th quarter. Renaissance Technologies LLC now owns 164,513 shares of the company’s stock worth $86,000 after buying an additional 138,625 shares in the last quarter. Tang Capital Management LLC grew its stake in shares of Relmada Therapeutics by 295.1% in the 4th quarter. Tang Capital Management LLC now owns 200,825 shares of the company’s stock worth $104,000 after buying an additional 150,000 shares in the last quarter. Finally, AdvisorShares Investments LLC grew its stake in shares of Relmada Therapeutics by 206.5% in the 4th quarter. AdvisorShares Investments LLC now owns 210,068 shares of the company’s stock worth $109,000 after buying an additional 141,540 shares in the last quarter. 45.24% of the stock is owned by hedge funds and other institutional investors.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.